Mia T Minen1, Ariana Gopal1, Gabriella Sahyoun1, Eric Stieglitz1, John Torous1. 1. Departments of Neurology and Population Health, New York University Langone Health (Minen); City College of New York (Gopal); Barnard College, New York (Sahyoun); and Department of Psychiatry, Beth Israel Deaconess Medical Center, Boston (Torous).
Abstract
OBJECTIVE: There are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and intervention), the data collected, and any privacy policies. METHODS: This was a cross-sectional study of apps for the five most disabling neuropsychiatric conditions per the World Health Organization: stroke, migraine, depression, Alzheimer's disease and dementia, and anxiety. Up to 15 apps in the U.S. Google Play and Apple app stores were selected based on the following prespecified inclusion criteria: the app appeared in the top 50 search results, offered intervention or tracking capabilities, and listed the condition in the app title or description. Exclusion criteria were <$5.00 to purchase, solely motor versus cognitive-based intervention, or designed for use by caregivers or health care providers. Data abstracted included function, behavior change rewards, and information about intervention, privacy policy, and payment. RESULTS: Eighty-three apps were reviewed (stroke, N=8; migraine, N=25; Alzheimer's disease and dementia, N=8; depression, N=7; anxiety, N=14; apps targeting depression and anxiety, N=21). Sixty-nine percent of apps had an intervention component, 18% were deemed evidence based, 77% had a privacy policy, 70% required payment for access to all features, and 19% rewarded user behavior changes. CONCLUSIONS: Most apps on the market targeted migraine, depression, and anxiety and contained interventions, although most of the interventions did not appear to be evidence based. Additionally, although most apps had privacy policies, lay people may have difficulty understanding these policies due to their complexities.
OBJECTIVE: There are more than 325,000 health-related smartphone applications (apps) on the market. To better understand the apps currently on the market for the five most disabling neuropsychiatric conditions, the authors conducted a study investigating their intended uses (target population and intervention), the data collected, and any privacy policies. METHODS: This was a cross-sectional study of apps for the five most disabling neuropsychiatric conditions per the World Health Organization: stroke, migraine, depression, Alzheimer's disease and dementia, and anxiety. Up to 15 apps in the U.S. Google Play and Apple app stores were selected based on the following prespecified inclusion criteria: the app appeared in the top 50 search results, offered intervention or tracking capabilities, and listed the condition in the app title or description. Exclusion criteria were <$5.00 to purchase, solely motor versus cognitive-based intervention, or designed for use by caregivers or health care providers. Data abstracted included function, behavior change rewards, and information about intervention, privacy policy, and payment. RESULTS: Eighty-three apps were reviewed (stroke, N=8; migraine, N=25; Alzheimer's disease and dementia, N=8; depression, N=7; anxiety, N=14; apps targeting depression and anxiety, N=21). Sixty-nine percent of apps had an intervention component, 18% were deemed evidence based, 77% had a privacy policy, 70% required payment for access to all features, and 19% rewarded user behavior changes. CONCLUSIONS: Most apps on the market targeted migraine, depression, and anxiety and contained interventions, although most of the interventions did not appear to be evidence based. Additionally, although most apps had privacy policies, lay people may have difficulty understanding these policies due to their complexities.
Authors: Timothy M Dall; Michael V Storm; Ritashree Chakrabarti; Oksana Drogan; Christopher M Keran; Peter D Donofrio; Victor W Henderson; Henry J Kaminski; James C Stevens; Thomas R Vidic Journal: Neurology Date: 2013-04-17 Impact factor: 9.910
Authors: Ying Lau; Tha Pyai Htun; Suei Nee Wong; Wai San Wilson Tam; Piyanee Klainin-Yobas Journal: J Med Internet Res Date: 2017-04-28 Impact factor: 5.428
Authors: Jennifer K Carroll; Anne Moorhead; Raymond Bond; William G LeBlanc; Robert J Petrella; Kevin Fiscella Journal: J Med Internet Res Date: 2017-04-19 Impact factor: 5.428
Authors: Michael Bauer; Tasha Glenn; John Geddes; Michael Gitlin; Paul Grof; Lars V Kessing; Scott Monteith; Maria Faurholt-Jepsen; Emanuel Severus; Peter C Whybrow Journal: Int J Bipolar Disord Date: 2020-01-10
Authors: Mia T Minen; Christina L Szperka; Kayla Kaplan; Annika Ehrlich; Nina Riggins; Paul Rizzoli; Lauren Doyle Strauss Journal: Headache Date: 2021-07-26 Impact factor: 5.311